通过使用手性Ru(II)催化剂和HCO 2 H / Et 3 N的共沸溶液作为氢供体,通过动态动力学拆分,开发了β-酮磺酰胺的高度对映选择性转移加氢反应,可提供良好的α-取代的β-羟基磺酰胺产生具有优异的非对映选择性和对映选择性的产物。该方法具有条件温和,操作简便,底物范围广的特点,可以在合成天然产物和含有α-取代的β-羟基磺酰胺核心的生物活性化合物中找到广泛的应用。
Photoredox-Catalyzed Generation of Sulfamyl Radicals: Sulfonamidation of Enol Silyl Ether with Chlorosulfonamide
作者:Qiyu Luo、Runyu Mao、Yan Zhu、Yonghui Wang
DOI:10.1021/acs.joc.9b02062
日期:2019.11.1
A novel and practical photoredox-catalyzed generation of sulfamyl radicals followed by radical sulfonamidation of enolsilylether has been described. Diverse functionalized β-ketosulfonamides were prepared in modest to excellent yields under mild and economic reaction conditions through the present catalytic protocol. Furthermore, the methodology developed provides an efficient and convenient approach
[EN] HSP70 INHIBITORS AND METHODS OF USING SAME<br/>[FR] INHIBITEURS DE HSP70 ET LEURS MÉTHODES D'UTILISATION
申请人:THE WISTAR INST
公开号:WO2021202540A1
公开(公告)日:2021-10-07
The disclosure provides compounds, and compositions comprising such compounds, that can be used to treat cancer, especially colorectal cancer (CRC). In certain embodiments, the compounds of the disclosure inhibit HSP70. In other embodiments, the compounds of the disclosure promote or increase immune cell recruitment to a cancer. In yet other embodiments, the compounds of the disclosure promote or increase immune cell infiltration in a cancer.
A straightforward synthesis of 5-sulfonamidomethyl substituted 4,7-dihydroazolo[1,5-<i>a</i>]pyrimidines
作者:Elena H. Shvets、Anastasiia V. Pidvorotnia、Olesia G. Kulyk、Alexander V. Mazepa、Maksim A. Kolosov
DOI:10.1080/00397911.2020.1821224
日期:2021.1.2
4,7-Dihydroazolo[1,5-a]pyrimidin-5-ylmethanesulfonamides are side-products of the three-component Biginelli-like reaction of aminoazoles, aldehydes and N,N-dialkyl-2-ketomethanesulfonamides. Herein...
Hepatoselectivity of statins: Design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors
作者:William K.C. Park、Robert M. Kennedy、Scott D. Larsen、Steve Miller、Bruce D. Roth、Yuntao Song、Bruce A. Steinbaugh、Kevin Sun、Bradley D. Tait、Mark C. Kowala、Bharat K. Trivedi、Bruce Auerbach、Valerie Askew、Lisa Dillon、Jeffrey C. Hanselman、Zhiwu Lin、Gina H. Lu、Andrew Robertson、Catherine Sekerke
DOI:10.1016/j.bmcl.2007.11.124
日期:2008.2
4-Sulfamoyl pyrroles were designed as novel hepatoselective HMG-CoA reductase inhibitors (statins) to reduce myalgia, a statin-induced adverse effect. The compounds were prepared via a [3 + 2] cycloaddition of a Munchnone with a sulfonamide-substituted alkyne. We identified compounds with greater selectivity for hepatocytes compared to L6-myocytes than rosuvastatin and atorvastatin. There was an inverse correlation of myocyte potencies and ClogP values. A number of analogs were effective at reducing cholesterol in acute and chronic in vivo models but they lacked sufficient chronic in vivo activity to warrant further development. (C) 2007 Elsevier Ltd. All rights reserved.